Angioimmunoblastic T-cell lymphoma is a follicular T-helper–derived neoplasm displaying a peculiar morphologic appearance and biological complexity. New mutations have been described that contribute to elucidating the underlying pathogenetic events. The disease behaves aggressively and typically affects elderly patients. The outcomes reported with anthracycline-containing regimens are poor; therefore autologous transplantation in first remission should be offered whenever possible. Newer approaches are urgently needed for relapsed and refractory patients. Newly approved agents show activity in pretreated patients but response durations are short. Innovative induction strategies (CHOP + biologic agent) should be designed to enhance response quality, facilitate transplantation, and prolong survival.
Broccoli, A., Zinzani, P.L. (2017). Angioimmunoblastic T-Cell Lymphoma. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 31(2), 223-238 [10.1016/j.hoc.2016.12.001].
Angioimmunoblastic T-Cell Lymphoma
BROCCOLI, ALESSANDRO;ZINZANI, PIER LUIGI
2017
Abstract
Angioimmunoblastic T-cell lymphoma is a follicular T-helper–derived neoplasm displaying a peculiar morphologic appearance and biological complexity. New mutations have been described that contribute to elucidating the underlying pathogenetic events. The disease behaves aggressively and typically affects elderly patients. The outcomes reported with anthracycline-containing regimens are poor; therefore autologous transplantation in first remission should be offered whenever possible. Newer approaches are urgently needed for relapsed and refractory patients. Newly approved agents show activity in pretreated patients but response durations are short. Innovative induction strategies (CHOP + biologic agent) should be designed to enhance response quality, facilitate transplantation, and prolong survival.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
